

# **EXHIBIT A**

John R. Manthei  
john.manthei@lw.com

555 Eleventh Street, N.W., Suite 1000  
Washington, D.C. 20004-1304  
Tel: +1.202.637.2200 Fax: +1.202.637.2201  
www.lw.com

**LATHAM & WATKINS LLP**

FIRM / AFFILIATE OFFICES

|              |                  |
|--------------|------------------|
| Beijing      | Moscow           |
| Boston       | Munich           |
| Brussels     | New York         |
| Century City | Orange County    |
| Chicago      | Paris            |
| Dubai        | Riyadh           |
| Düsseldorf   | San Diego        |
| Frankfurt    | San Francisco    |
| Hamburg      | Seoul            |
| Hong Kong    | Shanghai         |
| Houston      | Silicon Valley   |
| London       | Singapore        |
| Los Angeles  | Tokyo            |
| Madrid       | Washington, D.C. |
| Milan        |                  |

May 16, 2019

**EXPEDITED TREATMENT REQUESTED**

Food and Drug Administration  
Division of Freedom of Information  
Office of the Executive Secretariat, OC  
5630 Fishers Lane, Room 1035  
Rockville, MD 20857

Re: Freedom of Information Act Request

To Whom It May Concern:

Pursuant to the federal Freedom of Information Act (“FOIA”), 5 U.S.C. § 552 *et seq.*, Latham & Watkins LLP (“Latham”) requests copies of the records described below, as well as expedited processing of this request. If Latham’s request is denied in whole or in part, please justify all denials by reference to specific exemptions under FOIA. Please also release all segregable portions of otherwise exempt material. Latham will pay all necessary fees. Specifically, this letter requests:

All records associated with any Investigational New Drug Applications and New Drug Applications, including original submission and all amendments, for any drug containing amifampridine, including, but not limited to, formal and informal correspondence with the Food and Drug Administration; meeting requests, briefing materials, meeting minutes; and the review package, including approval letters, labeling, and application review files (e.g., summary review(s), clinical pharmacology and biopharmaceutics review(s), medical review(s), chemistry review(s), statistical review(s), non-clinical review(s), risk assessment and risk mitigation review(s), proprietary name review(s), other review(s), administrative documents and correspondence, etc.).

**LATHAM & WATKINS** LLP

I would appreciate communication by email or telephone, rather than postal mail. Please feel free to contact me directly with any questions at 202.637.2211 or john.manthei@lw.com. Thank you for your assistance.

Best regards,

A handwritten signature in black ink that reads "John Manthei" followed by a stylized monogram "JM".

John R. Manthei  
of LATHAM & WATKINS LLP